Nonclinical Results Presented at AAPS 2026

Dong-A ST confirmed in a nonclinical study the potential to develop icotrokinra, an ingredient in an oral psoriasis treatment, as a topical formulation applied to the skin.

Dong-A ST Confirms Potential to Develop 'Icotrokinra' as a Topical Treatment View original image

On October 27, Dong-A ST said it had presented the findings in a poster at AAPS PharmSci 360 2026, a conference of the American Association of Pharmaceutical Scientists (AAPS) being held in New Orleans, U.S., from October 25 to 28 local time. The researchers assessed skin penetration and retention outside the human body and developed a topical formulation that can deliver icotrokinra through the skin. In an animal model with induced skin inflammation, the formulation alleviated inflammation and suppressed the gene expression of IL-17A, IL-17F and IL-22, inflammatory cytokines associated with psoriasis.


Icotrokinra is an oral peptide that selectively binds to the interleukin-23 (IL-23) receptor, which transmits inflammatory signals, and blocks those signals. An oral treatment based on the ingredient received approval from the U.S. Food and Drug Administration (FDA) in March 2026. The presentation was delivered by Kim Haeseon, a senior researcher on Dong-A ST's drug delivery system (DDS) team.


The market for treatments for inflammatory skin conditions such as psoriasis is growing as formulations diversify to include oral and topical medications. Global investment bank Bank of America forecasts peak annual sales of $4.5 billion for an oral treatment based on icotrokinra. In the topical market, Incyte's JAK inhibitor Opzelura generated about $678 million in sales last year, while Organon's Vtama generated about $128 million.



A Dong-A ST official said, "For more than a decade, we have built up our drug delivery technology and R&D capabilities through research into a range of formulations, including patches, transdermal drug delivery and topical products. Building on our accumulated technology and experience, we will continue to pursue the development of new formulations for a variety of drugs."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing